Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MiNK Therapeutics, Inc.INKT · Entity 52 | Director | September 01, 2023 | September 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MiNK Therapeutics, Inc.
Report date September 01, 2023 · Filed September 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 41,193 |
Reported balance
After 2023-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-09-01 · Grant · Acquired 9,846 · Balance 41,193 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. F2: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 7,987 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 31,347 instead of 31,528 as erroneously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
F2: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 7,987 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 31,347 instead of 31,528 as erroneously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Sep 6, 2023 17:01 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon stock | 9,846 | $1.46 | $14,375.16 |
DisclosureSEC source: 0000950170-23-046775 · ownership.xml · nonDerivative · entry 1 Baldoni John · CIK 0001851248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,193 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. F2 · balance_after: In Table 1 of the Form 4 filed on June 2, 2023, the amount of securities acquired and price (column 4) and amount of securities beneficially owned following reported transaction (column 5) were erroneously reported. On June 1, 2023, 7,987 RSUs were acquired at a price of $1.80 each, resulting in a total amount of securities beneficially owned following the reported transaction of 31,347 instead of 31,528 as erroneously reported. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:07 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0000899243-23-015839 · doc4.xml · derivative · entry 1 Baldoni John · CIK 0001851248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 19:39 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon stock | 8,168 | $1.76 | $14,375.68 |
DisclosureSEC source: 0000899243-23-014409 · doc4.xml · nonDerivative · entry 1 Baldoni John · CIK 0001851248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,528 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 15:00 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon stock | 6,878 | $2.09 | $14,375.02 |
DisclosureSEC source: 0000899243-23-006915 · doc4.xml · nonDerivative · entry 1 Baldoni John · CIK 0001851248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,360 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 17:22 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon stock | 5,508 | $2.61 | $14,375.88 |
DisclosureSEC source: 0000899243-22-037655 · doc4.xml · nonDerivative · entry 1 Baldoni John · CIK 0001851248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,482 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 19:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon stock | 10,974 | $2.62 | $28,751.88 |
DisclosureSEC source: 0000899243-22-031534 · doc4.xml · nonDerivative · entry 1 Baldoni John · CIK 0001851248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,974 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 16:12 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0000899243-22-010706 · doc4.xml · derivative · entry 1 Baldoni John · CIK 0001851248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.